Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Change in Receivables (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Change in Receivables for 6 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 91.35% to $50000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 144.21% decrease, with the full-year FY2025 number at -$1.1 million, down 144.21% from a year prior.
  • Change in Receivables was $50000.0 for Q4 2025 at Lexicon Pharmaceuticals, down from $151000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.1 million in Q2 2024 to a low of -$1.0 million in Q1 2025.
  • A 3-year average of $196333.3 and a median of $254500.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 174.93% in 2024, then tumbled 298.84% in 2025.
  • Lexicon Pharmaceuticals' Change in Receivables stood at $692000.0 in 2023, then dropped by 16.47% to $578000.0 in 2024, then tumbled by 91.35% to $50000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Change in Receivables are $50000.0 (Q4 2025), $151000.0 (Q3 2025), and -$264000.0 (Q2 2025).